The entire collaboration is overseen by a Joint Steering Committee co-chaired by GSK’s Head of Advanced Manufacturing Technologies Mark Buswell and the Head of Department of Chemical Engineering at Imperial, Andrew Livingston.  The project is managed by the two Oversight Managers Magalie Rocheville, External Engagement Lead at GSK, and Vjera Magdalenic-Moussavi, Imperial’s Corporate Partnership Manager for the Faculty of Medicine.

Joint Steering Committee

Mark Buswell

Mark Buswell

Mark Buswell
(Co-Chair) - GSK Head of Discovery, Development and Laboratory Systsems IT

Andrew Livingston

Andrew Livingston

Andrew Livingston
(Co-Chair) - Head of Department of Chemical Engineering - Imperial

Ravi Rao

Ravi Rao

Ravi Rao
GSK Medical Development Leader, Immuno-inflamation

Richard Marshall

Richard Marshall

Richard Marshall
GSK Head of Fibrosis DPU

Robin Carr

Robin Carr

Robin Carr
GSK Head of Molecular Discovery Research

Molly Stevens

Molly Stevens

Molly Stevens
Prof. of Biomedical Materials & Regenerative Medicine - Imperial

Charles Coombes

Charles Coombes

Charles Coombes
Director of The CRUK Cancer Centre - Imperial

Dorian Haskard

Dorian Haskard

Dorian Haskard
Head of Vascular Sciences - Imperial

Oversight Managers

Vjera Magdalenic-Moussavi

Vjera Magdalenic-Moussavi

Vjera Magdalenic-Moussavi
Oversight Manager - Imperial

Magalie Rocheville

Magalie Rocheville

Magalie Rocheville
Oversight Manager - GSK

Project Leads

EML 1

Individual projects are led by two project leads, one from Imperial and one from GSK.

EML 1 Project Leads:

Peter DiMaggio (Imperial)

David Tew (GSK)

EML 2

Individual projects are led by two project leads, one from Imperial and one from GSK.

EML 2 Project Leads:

Molly Stevens (Imperial)

Steve Hood (GSK)

EML 3

Individual projects are led by two project leads, one from Imperial and one from GSK.

EML 3 Project Leads:

Tom Welton (Imperial)

Lisa McQueen (GSK)